Risk biomarkers and current strategies for cancer chemoprevention

Journal of Cellular Biochemistry

Volumn 63, Issue SUPPL. 25, 1996, Pages 1-14

  Kelloff, Gary J ^a   Boone, Charles W ^a   Crowell, James A ^a   Nayfield, Susan G ^a   Hawk, Ernest ^a   Malone, Winfred F ^a   Steele, Vernon E ^a   Lubet, Ronald A ^a   Sigman, Caroline C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

Author keywords

chemoprevention; genetic regulatory biomarkers; high risk cohorts; intraepithelial neoplasia; phase II clinical trials; risk biomarkers

Indexed keywords

ACETYLCYSTEINE; AFLATOXIN B1; CALCITRIOL; CALCIUM; COLECALCIFEROL; EFLORNITHINE; EXEMESTANE; FENRETINIDE; FOLIC ACID; OLTIPRAZ; PHENETHYL ISOTHIOCYANATE; PIROXICAM; PRASTERONE; SULINDAC; TAMOXIFEN; TUMOR MARKER;

CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARCINOGEN DNA INTERACTION; CLINICAL TRIAL; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT;

EID: 85086684112     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-4644(1996)25+<1::aid-jcb1>3.0.co;2-4     Document Type: Review

References (73)

1. Henderson BE, Ross RK, Shibata A, Paganini-Hill A, Yu MC (1992): Environmental carcinogens and anticarcinogens. In Wattenberg L, Lipkin M, Boone CW, Kelloff GJ (eds): "Cancer Chemoprevention." Boca Raton, FL: CRC Press, pp 3-17.
2. Doll R, Peto R (1981): The causes of cancer. J Natl Cancer Inst 66:1191-1308.
3. Li FP (1988): Cancer families: Human models of susceptibility to neoplasia - The Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res 48:5381-5386.
4. Wingo PA, Tong T, Bolden S (1995): Cancer statistics, 1995. CA Cancer J Clin 45:8-30.
5. Ruddon RW (1995): The epidemiology of human cancer. In: "Cancer Biology." New York: Oxford University Press, pp 19-60.
6. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Sigman CC (1994): Chemopreventive drug development: Perspectives and progress. Cancer Epidemiol Biomarkers Prev 3:85-98.
7. Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Sigman CC (1994): Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials. Cancer Res 54:2015S-1024S.
8. Kelloff GJ, Johnson JR, Crowell JA, Boone CW, DeGeorge JJ, Steele VE, Mehta MU, Temeck JW, Schmidt WJ, Burke G, Greenwald P, Temple RJ (1995): Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 4:1-10.
9. Hulka BS, Wilcosky T (1988): Biological markers in epidemiologic research. Arch Environ Health 43:83-89.
10. Lowy DR, Kirnbauer R, Schiller JT (1994): Genital human papilloma virus infection. Proc Natl Acad Sci U S A 91:2436-2440.
11. De Flora S, Cesarone CF, Balanaky RM, Albini A, D'Agostini F, Bennicelli C, Bagnasco M, Camoirano A, Scatolini L, Rovida A, Izzotti A (1995): Chemopreventive properties and mechanisms of N-acetylcysteine. The experimental background. J Cell Biochem 22 (Suppl):33-41.
12. Puisieux A, Lim S, Groopman J, Ozturk M (1991): Selective targeting of p53 gene mutational hotspots in human cancer by etiologically defined carcinogens. Cancer Res 51:6185-6189.
13. Cerutti P, Hussain P, Pourzand C, Aguilar F (1994): Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. Cancer Res 54:1934S-1938S.
14. Taylor JA, Watson MA, Devereux TR, Michels RY, Saccomanno G, Anderson M (1994): p53 Mutation hotspot in radon-associated lung cancer. Lancet 343:86-87.
15. Fearon ER, Vogelstein B (1990): A genetic model for colorectal tumorigenesis. Cell 61:759-767.
16. Goyette MC, Stanbridge EJ (1992): The role of tumor suppressor genes in human colorectal cancer. In Steele VE, Boone CW, Stoner GD, Kelloff GJ (eds): "Cellular and Molecular Targets for Chemoprevention." Boca Raton, FL: CRC Press, pp 133-145.
17. King M-C (1992): Breast cancer genes: How many, where and who are they? Nat Genet 2:89-90.
18. Smith SA, Easton DF, Evans DGR, Ponder BAJ (1992): Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 2:128-131.
19. Easton DF, Bishop DT, Ford D, Crockford GP (1993): Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52:678-701.
20. Easton DF, Ford D, Bishop DT (1995): Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56:265-271.
21. Goldgar DE, Fields P, Lewis CM, Tran TD, Cannon-Albright LA, Ward JH, Swensen J, Skolnick MH (1994): A large kindred with 17q-linked breast and ovarian cancer: Genetic, phenotypic, and genealogical analysis. J Natl Cancer Inst 86:200-209.
22. Collins FS (1996): BRCA1 - Lots of mutations, lots of dilemmas. N Engl J Med 334:186-188.
23. Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R (1993). The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-1038.
24. Papadopoulos N, Nicolaides NC, Wei Y-F, Ruhen SM, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Hamilton SR, Petersen GM, Watson P, Lynch HT, Peltomäki P, Mecklin J-P, de la Chapelle A, Kinzler KW, Vogelstein B (1993): Mutation of a mutL homolog in hereditary colon cancer. Science 263:1625-1629.
25. Inaba T, Nebert DW, Burchell B, Watkins PB, Goldstein JA, Bertilsson L, Tucker GT (1995): Pharmacogenetics in clinical pharmacology and toxicology. Can J Physiol Pharmacol 73:331-338.
26. Hayes JD, Pulford DJ (1995): The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445-600.
27. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991): p53 Mutations in human cancers. Science 253: 49-53.
28. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994): Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
29. Cooper GM (1995): "Oncogenes." 2nd Ed. Boston: Jones and Bartlett, p 384.
30. Spitz MR, Bondy ML (1993): Genetic susceptibility to cancer. Cancer 72:991-995.
31. Boone CW, Kelloff GJ, Steele VE (1992): Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res 52:1651-1659.
32. Boone CW, Kelloff GJ, Freedman LS (1993): Intraepithelial and postinvasive neoplasia as a stochastic contimium of clonal evolution, and its relationship to mechanisms of chemopreventive drug action. J Cell Biochem 17G (Suppl):14-25.
33. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Doody LA (1994): Surrogate endpoint biomarkers for Phase II cancer chemoprevention trials. J Cell Biochem 19 (Suppl):1-9.
34. Rao JY, Hemstreet GP III, Hurst RE, Bonner RB, Min KW, Jones PL (1991): Cellular F-actin levels as a marker for cellular transformation: Correlation with bladder cancer risk. Cancer Res 51:2762-2767.
35. Hemstreet GP III, Rao JY, Hurst RE, Bonner RB, Jones PL, Vaidya AM, Fradet Y, Moon RC, Kelloff GJ (1992): Intermediate endpoint biomarkers for chemoprevention. J Cell Biochem 161 (Suppl):93-110.
36. Tockman MS, Erozan YS, Gupta P, Piantadosi S, Mulshine JL, Ruckdeschel JC (1994): The early detection of second primary lung cancers by sputum immunostaining. LCEWDG Investigators. Lung Cancer Early Detection Group. Chest 106:385S-390S.
37. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D (1994): Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 91:9871-9875.
38. Partin AW, Getzenberg RH, CarMichael MJ, Vindivich D, Yoo J, Epstein JI, Coffey DS (1993): Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 53:744-746.
39. Sommerfeld H-J, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS (1996): Telomerase activity: A prevalent marker of malignant human prostate tissue. Cancer Res 56:218-222.
40. Hong WK, Lippman SM, Itri TM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, Dimery IW, Brown BW, Goepfert H (1990): Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801.
41. Lippman SM, Benner SE, Hong WK (1993): Chemoprevention. Strategies for the control of cancer. Cancer 72:984-990.
42. Veronesi U, De Palo G, Costa A, Del Vecchio M, Marubini E, de Yoldi GFC, Attili A, Mascotti G, Moglia D, Magni A, Cerrotta A, Delle Grottaglie M, Crippa A, Palvarini M, Maltoni C, Del Turco MR, Saccani G, Boccardo F (1992): Controlled clinical trials with fenretinide in the prevention of contralateral breast cancer. Rationale, design, methodological approach and accrual. Serono Symp Publ Raven Press 79:243-259.
43. Harris AL, Neal DE (1992): Bladder cancer - field versus clonal origin. N Engl J Med 326:759-761.
44. Herr HW, Jakse G, Sheinfeld J (1990): The T1 bladder tumor. Semin Urol 8:254-261.
45. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989): Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886.
46. Shopland DR, Eyre HJ, Pechacek TF (1991): Smoking-attributable cancer mortality in 1991: Is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst 83:1142-1148.
47. Frykberg ER, Bland KI (1993): In situ breast carcinoma. Adv Surg 26:29-72.
48. Chanen W (1990): The CIN saga - The biological and clinical significance of cervical intraepithelial neoplasia. Aust NZ J Obstet Gynaecol 30:18-23.
49. Day DW, Morson BC (1978): The adenoma-carcinoma sequence. In Bennington JL (ed): "The Pathogenesis of Colorectal Cancer." Philadelphia, PA: W.B. Saunders Co., pp 58-71.
50. Page DL, Dupont WD, Rogers LW, Rados MS (1985): Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55:2698-2708.
51. Bostwick DG (1992): Prostatic intraepithelial neoplasia (PIN): Current concepts. J Cell Biochem 16H (Suppl):10-19.
52. Bruzzi P, Bonelli L, Costantini M, Sciallero S, Boni L, Aste H, Gatteschi B, Naldoni C, Bucchi L, Casetti T, Bertinelli E, Lanzanova G, Onofri P, Parri R, Rinaldi P, Castiglione G, Mantellini P, Giannini A (1995): A Multicenter Study of Colorectal Adenomas - Rationale, objectives, methods and characteristics of the study cohort. Tumori 81:157-163.
53. Villeneuve PJ, Mao Y (1993): Lifetime probability of developing lung cancer, by smoking status, Canada. Can J Public Health 85:385-388.
54. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Group (1994): The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers m male amokers. N Engl J Med 330:1029-1035.
55. Omenn GS, Goodman G, Thornquist M, Grizzle J, Rosenstock L, Barnhart S, Balmes J, Cherniack MG, Cullen MR, Glass A, Keogh J, Meyskens F Jr, Valanis B, Williams J Jr (1994): The β-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: Smokers and asbestos-exposed workers. Cancer Res 54:2038S-2043S.
56. Sidransky D (1995): Molecular markers in cancer diagnosis. J Natl Cancer Inst Monogr 17:27-29.
57. Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56:710-714.
58. Palcic B (1994): Nuclear texture: Can it be used as a surrogate endpoint biomarker? J Cell Biochem 19 (Suppl):40-46.
59. van Diest PJ, Baak JPA (1994): Biomarkers of breast hyperplasias and in situ carcinomas: An overview. J. Cell Biochem 19 (Suppl):99-104.
60. Bacus JW, Bacus JV (1994): Quality control in image cytometry: DNA ploidy. J Cell Biochem 19 (Suppl):153-164.
61. Slaughter DP, Southwick HW, Smejkel W (1953): "Field cancerization" in oral stratified squamous epithelium: Clinical implications of multicentric origin. Cancer 6:963-968.
62. Benner SE, Lippman SM, Hong WK (1992): Chemoprevention strategies for lung and upper aerodigestive tract cancer. Cancer Res 52:2758S-2763S.
63. Schatzkin A, Goldstein A, Freedman LS (1995): What does it mean to be a cancer gene carrier? Problems in establishing causality from the molecular genetics of cancer. J Natl Cancer Inst 87:1126-1130.
64. Baker SG, Freedman LS (1995): Potential impact of genetic testing on cancer prevention trials, using breast cancer as an example. J Natl Cancer Inst 87:1137-1144.
65. Kensler TW, Helzlsouer KJ (1995): Oltipraz: Clinical opportunities for cancer chemoprevention. J Cell Biochem 22 (Suppl):101-107.
66. Vainio H, Heseltine E, Wilbourn J (1993): Report on an IARC Working Group meeting on some naturally occurring substances. Int J Cancer 53:535-537.
67. 1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiolthione. Carcinogenesis 6:759-763.
68. Kensler TW, Egner PA, Dolan PM, Groopman JD, Roebuck BD (1987): Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res 47: 4271-4277.
69. 1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): Predictive role for short-term molecular dosimetry. Cancer Res 51: 5501-5506.
70. Groopman JD, Jiaqi Z, Donahue PR, Pikul A, Lishheng Z, Jun-shi C, Wogan GN (1992): Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China. Cancer Res 52:45-52.
71. 7-guanine and serum aflatoxin - albumin adducts predicts chemoprotection by 1,2-dithiole-3-thione in rats. Carcinogenesis 13:101-106.
72. Primiano T, Egner PA, Sutter TR, Kelloff GJ, Roebuck BD, Kensler TW (1995): Intermittent dosing with oltipraz: Relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res 55:4319-4324.
73. Fabian CJ, Zalles C, Kamel S, McKittrick R, Moore WP, Zeiger S, Simon C, Kimler B, Cramer A, Garcia F, Jewell W (1993): Biomarkers and cytologic abnormalities in women at high and low risk for breast cancer. J Cell Biochem 17G (Suppl):153-160.